GlassScriptPhysician profile
Kimberly Mcgowan
NPI 1831148683
$1,782.18
in general payments reported to CMS, 2019-2025
19 companies · $587 in 2025
The $587 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.23 · 2021: $90.12 · 2022: $126 · 2023: $426 · 2024: $462 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $383.78 | 2021-2025 | Aptima |
| Coopersurgical, INC. | $215.18 | 2023-2025 | Endosee, Summit Doppler, Paragard T 380a |
| Abbvie INC. | $202.21 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Myriad Women'S Health, INC. | $157.33 | 2023 | Myrisk |
| Astellas Pharma US INC | $139.85 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $137.69 | 2023-2025 | Slynd |
| Sage Therapeutics, LLC | $120.16 | 2025 | Zurzuvae |
| Organon LLC | $110.47 | 2021-2025 | Jada System, Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $62.62 | 2021-2023 | |
| Smith+Nephew, INC. | $47.46 | 2019-2025 | Pico 14 |
| Supernus Pharmaceuticals, INC. | $42.20 | 2025 | Qelbree |
| Millicent US INC | $30.62 | 2023-2025 | Femring, Intrarosa |
| Ascend Therapeutics US, LLC | $24.46 | 2019 | |
| Medtronic, INC. | $23.55 | 2022 | |
| Mayne Pharma Commercial LLC | $22.88 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $20.03 | 2022 | |
| Merck Sharp & Dohme LLC | $17.44 | 2023 | Gardasil 9 |
| Boston Scientific Corporation | $13.15 | 2019 | |
| Allergan, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Mcgowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.